Envoy Medical SEC Filings

Envoy Medical, Inc. (COCH) is offering securities in a prospectus supplement that discloses a public offering price of $0.1131 per unit, placement agent fees of $340,001, and proceeds to the company before expenses of $3,660,007. The document lists intended uses of proceeds including continued R&D and clinical trials for the Acclaim CI product candidate, seeking regulatory approvals outside the United States, building sales and distribution infrastructure, reliance on third-party suppliers, IP protection, hiring personnel, and general public-company infrastructure.

The filing enumerates material risk factors affecting investors: company financial performance; market-price volatility of Class A common stock; regulatory, clinical and design-change risks for medical devices; reimbursement and competitive risks; supplier or production disruptions; capital-raising needs; interest rate, tariff and tax changes; legal and regulatory proceedings; potential loss of intellectual property; and catastrophic events such as war or terrorism. The supplement also details outstanding and potential dilutive instruments including multiple classes of warrants, options, Series A preferred conversion, and other securities.

Envoy Medical, Inc. is asking stockholders to approve actions tied to securities issued in a September 23, 2025 offering. The company completed a Registered Offering of Class A common stock at $1.31 per share and a Private Placement that delivered 5,725,206 Private Warrants. Stockholder approval would enable exercisability and issuance of shares underlying those warrants, including Placement Agent Warrants equal to 7.5% of exercised Private Warrants. The Private Warrants carry an exercise price of $1.6375, become exercisable on the Stockholder Approval Date and expire on the earlier of two years after effectiveness or September 22, 2030. The Private Warrants include ownership caps of 4.99% (or 9.99% if elected) to limit any purchaser’s post-exercise beneficial ownership. A stockholder vote must be received by 11:59 p.m. ET on November 25, 2025. The proxy notes broker non-votes do not affect the outcome and discusses householding and delivery of proxy materials.

Envoy Medical, Inc. files a prospectus supplement describing a securities offering and related risk factors. The company lists numerous operational and industry risks including regulatory uncertainty for medical devices, potential product design changes, supplier and manufacturing disruptions, reimbursement policy shifts, competition and alternative therapies, capital needs and financing availability, intellectual property risks, legal and regulatory proceedings, and catastrophic events. The prospectus also details planned uses of proceeds to advance Acclaim CI clinical development, pursue additional regulatory approvals, build commercial infrastructure, rely on third-party suppliers, expand intellectual property, and hire personnel. The filing discloses potential dilution from various warrants, options and convertible preferred shares (examples: 14,166,666 Public Warrant shares; 3,104,511 Meteora Warrant shares; 3,588,406 shares on conversion of Series A Preferred; and equity incentive plan options). It incorporates multiple prior reports by reference.

Envoy Medical, Inc. disclosed that it and certain related parties entered into a Voting and Warrant Extension Agreement dated September 4, 2025. The agreement extends the expiration date of warrants held by GAT Funding, LLC and related Taylor parties to December 31, 2028. Prior to the extension those warrants had staggered expirations between February 27, 2026 and June 26, 2027.

The filing identifies Glen A. Taylor and affiliated entities as the warrant holders and notes Mr. Taylor directly or indirectly owns approximately 47.8% of the Company’s outstanding Class A Common Stock. The document is filed on Form 8-K and includes the Voting and Warrant Extension Agreement as an exhibit.

Envoy Medical, Inc. (COCH) insider filing by Glen A. Taylor reports multiple warrant amendments and related ownership disclosures. The filing shows Mr. Taylor as a director and >10% owner through direct holdings and indirect interests via Taylor Sports Group and GAT Funding, LLC. He disposed of 2,953,607 Class A shares and retains indirect and direct beneficial ownership positions: 2,526,058 shares indirectly and 4,810,384 shares indirectly via GAT Funding, LLC. The Form 4 documents cancellation of several "old" warrants and issuance of replacement warrants on 09/04/2025; replacement warrants are fully exercisable and, for several series, extend exercise expirations to 12/31/2028 while some near-term cancelled warrants show zero remaining post-transaction balances.